Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Med Virol
    September 2025
  1. BERTONI C, Diotallevi S, Lolatto R, Piromalli G, et al
    Hepatitis B Viral Rebound in People With HIV Under HBV-Active Antiretroviral Therapy.
    J Med Virol. 2025;97:e70573.
    >> Share

  2. KIM H, Kim JY, Choi HB, Lee JS, et al
    Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent.
    J Med Virol. 2025;97:e70584.
    >> Share

    July 2025
  3. HUNG CT, Wang LM, Lee YJ, Suk CW, et al
    Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study.
    J Med Virol. 2025;97:e70494.
    >> Share

    May 2025
  4. MAZZOTTA V, Lepri AC, Del Borgo C, Lanini S, et al
    Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials.
    J Med Virol. 2025;97:e70379.
    >> Share

  5. YANG H, Gao L, Xue Y, Zhang Z, et al
    Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.
    J Med Virol. 2025;97:e70377.
    >> Share

    April 2025
  6. HSU PY, Su HC, Ma MC, Chen CA, et al
    Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta-Analysis.
    J Med Virol. 2025;97:e70331.
    >> Share

  7. CHUANG CH, Wang YH, Yeh LT, Yeh CB, et al
    Long-Term Stroke and Mortality Risk Reduction Associated With Acute-Phase Paxlovid Use in Mild-to-Moderate COVID-19.
    J Med Virol. 2025;97:e70351.
    >> Share

    March 2025
  8. AZANZA JR, Gonzalez Del Castillo JM, Ferrando R, Molero JM, et al
    Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.
    J Med Virol. 2025;97:e70288.
    >> Share

  9. AMEGASHIE EA, Kwayisi-Darkwah CK, Adusei-Poku M, Sikeola RO, et al
    Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co-infected With Human Coronaviruses in Ghana.
    J Med Virol. 2025;97:e70301.
    >> Share

  10. CHIANG CM, Lin YJ, Liu WC, Chou TC, et al
    HBV Recurrence Detected by HBV-Related Serum Markers and Immune Escape Mutations in Chronic Hepatitis B Patients Following Liver Transplantation.
    J Med Virol. 2025;97:e70306.
    >> Share

    February 2025
  11. KIM LY, Kim JY, Yoo JJ, Kim SG, et al
    Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B.
    J Med Virol. 2025;97:e70187.
    >> Share

  12. YE J, Zhang R, Zhou J, Xu T, et al
    Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS-CoV-2 via Combined Experiments.
    J Med Virol. 2025;97:e70229.
    >> Share

    December 2024
  13. LIN W, He Y, Gu F, Hu F, et al
    Hepatic Flare Following Effective Antiretroviral Therapy Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection.
    J Med Virol. 2024;96:e70114.
    >> Share

    November 2024
  14. WANG J, Jiang H, Zhang G, Dai X, et al
    Real-World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation.
    J Med Virol. 2024;96:e70055.
    >> Share

  15. ZHAO H, He Y, Ling X, Hou H, et al
    Profiles of Lymphocyte Subtypes in HIV-Infected People With Different Immunologic Responses to Antiretroviral Therapy.
    J Med Virol. 2024;96:e70081.
    >> Share

    October 2024
  16. LV S, Lan Y, He Y, Li Q, et al
    Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China.
    J Med Virol. 2024;96:e29937.
    >> Share

  17. CHAIX ML, Terracol L, Nere ML, Stefic K, et al
    Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.
    J Med Virol. 2024;96:e29948.
    >> Share

  18. ALIDJINOU EK
    Comments on "High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence".
    J Med Virol. 2024;96:e29950.
    >> Share

  19. ANDREATTA K, D'Antoni ML, Chang S, Parvangada A, et al
    High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence.
    J Med Virol. 2024;96:e29899.
    >> Share

    August 2024
  20. LI J, Lv J, Yu F, Zhang Y, et al
    Temporal changes in plasma metabolic signatures to predict immune response of antiretroviral therapy among people living with HIV.
    J Med Virol. 2024;96:e29798.
    >> Share

  21. WANG Z, Wang W, Gao Z, Gao H, et al
    Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles.
    J Med Virol. 2024;96:e29830.
    >> Share

    July 2024
  22. SHIN H, Lim GS, Yoon JW, Ko Y, et al
    Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B.
    J Med Virol. 2024;96:e29760.
    >> Share

    June 2024
  23. CHEN IW, Yu TS, Lin CH, Hung KC, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.
    J Med Virol. 2024;96:e29718.
    >> Share

  24. MOOKO T, Bisiwe FB, Chikobvu P, Morobadi MD, et al
    The prevalence of HIV resistance mutations and their influence on the shedding of HIV-1 into peritoneal dialysis effluent.
    J Med Virol. 2024;96:e29734.
    >> Share

    May 2024
  25. WU JY, Chen CC, Liu MY, Hsu WH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    J Med Virol. 2024;96:e29662.
    >> Share

    March 2024
  26. XIE M, Wang Z, Zhao F, Li Y, et al
    Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.
    J Med Virol. 2024;96:e29502.
    >> Share

  27. YANG J, Xu S, Cheng J, Yin X, et al
    CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF.
    J Med Virol. 2024;96:e29516.
    >> Share

  28. TRUNFIO M, Tang B, Okwuegbuna O, Iudicello JE, et al
    Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers.
    J Med Virol. 2024;96:e29550.
    >> Share

    February 2024
  29. CHANG LC, Chen IW, Hung KC
    Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    J Med Virol. 2024;96:e29464.
    >> Share

  30. OMBELET S, Castanares-Zapatero D, Desimpel F, Hulstaert F, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    J Med Virol. 2024;96:e29434.
    >> Share

    January 2024
  31. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Veintimilla C, et al
    No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.
    J Med Virol. 2024;96:e29337.
    >> Share

  32. DURSTENFELD MS, Peluso MJ, Lin F, Peyser ND, et al
    Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    J Med Virol. 2024;96:e29333.
    >> Share

    December 2023
  33. ZHOU Y, Liu Y, Jiang L, Zhang R, et al
    Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    J Med Virol. 2023;95:e29318.
    >> Share

    November 2023
  34. CHEN YC, Hsu CW, Chien RN
    Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
    J Med Virol. 2023;95:e29213.
    >> Share

    October 2023
  35. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    >> Share

  36. LAGI F, Giacomelli A, Borghi V, Ciccullo A, et al
    Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    J Med Virol. 2023;95:e29149.
    >> Share

  37. OOMEN PGA, Dijkstra S, Hofstra LM, Nijhuis MM, et al
    Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study.
    J Med Virol. 2023;95:e29178.
    >> Share

    September 2023
  38. CASO JM, Fernandez-Ruiz M, Lopez-Medrano F, Caro-Teller JM, et al
    Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
    J Med Virol. 2023;95:e29082.
    >> Share

  39. BRUZZESI E, Gabrieli A, Bernasconi D, Marchetti G, et al
    HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    J Med Virol. 2023;95:e29114.
    >> Share

    August 2023
  40. LIU TH, Chuang MH, Wu JY, Huang PY, et al
    Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
    J Med Virol. 2023;95:e28992.
    >> Share

  41. WANG Y, Zhao D, Xiao W, Shi J, et al
    Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.
    J Med Virol. 2023;95:e29014.
    >> Share

    July 2023
  42. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
    J Med Virol. 2023;95:e28951.
    >> Share

    June 2023
  43. ZENG G, Wang L, Li J, Zhang Z, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
    J Med Virol. 2023;95:e28836.
    >> Share

  44. RANARD BL, Chow CC, Megjhani M, Asgari S, et al
    A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    J Med Virol. 2023;95:e28854.
    >> Share

  45. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e28869.
    >> Share

  46. WU JY, Liu MY, Liu TH, Chuang MH, et al
    Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
    J Med Virol. 2023;95:e28866.
    >> Share

  47. AMANI B, Akbarzadeh A, Amani B, Shabestan R, et al
    Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28889.
    >> Share

    May 2023
  48. LIU TH, Huang PY, Wu JY, Chuang MH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    J Med Virol. 2023;95:e28801.
    >> Share

    April 2023
  49. COX S, Margot N, Callebaut C
    Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    J Med Virol. 2023;95:e28723.
    >> Share

  50. DENG G, Li D, Sun Y, Jin L, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    J Med Virol. 2023;95:e28756.
    >> Share

  51. CHUANG MH, Wu JY, Liu TH, Hsu WH, et al
    Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28750.
    >> Share

  52. TIAN F, Chen Z, Feng Q
    Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28732.
    >> Share

    March 2023
  53. TRUNFIO M, Pinnetti C, Arsuffi S, Bai F, et al
    The Presence of Resistance-associated Mutations in Reverse Transcriptase Gene is Associated with Cerebrospinal Fluid HIV-1 Escape: a multicentric retrospective analysis.
    J Med Virol. 2023 Mar 26. doi: 10.1002/jmv.28704.
    >> Share

  54. SHARMA A, Roy S, Sharma R, Kumar A, et al
    Association of anti-viral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28671.
    >> Share

    February 2023
  55. GUO Y, Guo Y, Zhang Y, Li F, et al
    Factors Affecting Prolonged SARS-CoV-2 Infection and Development and Validation of Predictive Nomograms.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28550.
    >> Share

    January 2023
  56. QI T, Jin Y, Wang H, Liao Y, et al
    Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection.
    J Med Virol. 2023 Jan 18. doi: 10.1002/jmv.28497.
    >> Share

  57. CHEEMA HA, Jafar U, Sohail A, Shahid A, et al
    Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28471.
    >> Share

  58. SUDA G, Baba M, Yamamoto Y, Sho T, et al
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28452.
    >> Share

    December 2022
  59. WANG Y, Zhao D, Liu X, Chen X, et al
    Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28443.
    >> Share

  60. AMANI B, Amani B
    Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 : a rapid review and meta-analysis.
    J Med Virol. 2022 Dec 28. doi: 10.1002/jmv.28441.
    >> Share

  61. LAI CC, Hsueh PR
    Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28430.
    >> Share

  62. WANG Y, Chen X, Liu X, Zhao D, et al
    Nirmatrelvir-ritonavir might only be effective in elderly patients.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28418.
    >> Share

    October 2022
  63. VALENTINA M, Alessandro CL, Francesca C, Silvia R, et al
    Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    J Med Virol. 2022 Oct 2. doi: 10.1002/jmv.28186.
    >> Share

    July 2022
  64. LAN J, Li W, Yu R, Syed F, et al
    Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naive and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors.
    J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28005.
    >> Share

  65. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    >> Share

  66. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    >> Share

    June 2022
  67. AGUILAR G, Truong HM, Ovelar P, Samudio T, et al
    HIV Drug Resistance in Persons Initiating or Re-initiating First-line Antiretroviral Therapy in Paraguay: Results of a National Patient Survey.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27933.
    >> Share

  68. ASHURO AA, Zhang SC, Wang T, Chu QS, et al
    The Effect of protease inhibitors-based antiretroviral therapy on serum/plasma interleukin-6 levels among PLHIV: a systematic review and meta-analysis.
    J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27912.
    >> Share

    May 2022
  69. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    >> Share

    March 2022
  70. FIORE BD, Andrea V, Giuseppe P, Yagai B, et al
    Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27754.
    >> Share

  71. HASSANIAZAD M, Farshidi H, Gharibzadeh A, Bazram A, et al
    Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with covid-19: a randomized clinical trial.
    J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27724.
    >> Share

    February 2022
  72. CHIU W, Verschueren L, Eynde CVD, Buyck C, et al
    Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27683.
    >> Share

    December 2021
  73. WANG Z, Yang L
    In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27540.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016